Sunday 8 November 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRNHealthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- Revenue
- −20.4%
- EPS
- +103.1%
- Free cash flow
- +172.6%
Quarter to September 2026, against a year earlier
11.61
0.03
+0.26%
Follow AMRN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(8.21%) | (7.28%) | (5.97%) | (4.24%) | |
Piotroski F-Score |
7 | 6 | 6 | 6 | |
| (5.72%) | (5.17%) | (4.19%) | (2.96%) | ||
ROIC |
(20.04%) | (19.78%) | (19.79%) | (16.57%) | |
Return on Tangible Assets |
(8.52%) | (7.53%) | (6.18%) | (4.37%) | |
Average Days of Receivables |
216.68 | 181.95 | 182.11 | 231.24 | |
Free Cash Flow per Share |
0.32 | 1.22 | 0.75 | 1.79 | |
Free Cash Flow |
6.73 | 25.58 | 15.57 | 37.49 | |
| Other line items | |||||
Cash ROIC |
0.88% | 3.38% | 2.05% | 4.88% | |
Accounts Receivable Turnover |
1.72 | 2.02 | 1.76 | 1.47 | |
Accounts Payable Turnover |
2.16 | 2.20 | 3.40 | 2.70 | |
Inventory Turnover |
0.51 | 0.60 | 0.64 | 0.61 | |
Average Days of Payables |
178.43 | 170.22 | 63.47 | 141.88 | |
Days of Inventory on Hand |
770.73 | 648.97 | 554.01 | 557.48 | |
Tax Rate |
0.08 | 0.08 | 0.06 | 0.12 | |
Research and Development Expense of Revenue |
9.27% | 8.84% | 10.21% | 10.80% | |
Selling, General and Administrative Expense of Revenue |
53.83% | 45.92% | 44.60% | 44.12% | |
Share Based Compensation of Revenue |
6.52% | 5.51% | 4.30% | 4.21% | |
Operating CF/Net income |
(0.17) | (0.76) | (0.57) | (1.96) | |
Depreciation/Fixed assets |
252.33 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
10.30 | 10.35 | 8.94 | 8.43 | |
Operating CF per Share |
0.32 | 1.22 | 0.75 | 1.79 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026